• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $1,059 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-33 Mln

MannKind Corp (MNKD) Share Price

$4.50

As on 01-Mar-2024 16:04 EST

up-down-arrow $0.399.49%

  • Prev Close info

    $4.11

  • Day's Openinfo

    $4.15

  • Today's Highinfo

    $4.70

  • Today's Lowinfo

    $4.15

  • Today's Volumeinfo

    6,994,841

  • 52 Week rangeinfo

    $3.17 - 5.75

Please wait...

MannKind Corp (MNKD) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
MannKind Corp (MNKD)
23.63 34.73 24.31 -14.77 -7.63 20.25 -17.54
S&P BSE Sensex*
2.26 2.48 9.47 23.51 12.82 15.42 13.43
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 04-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
MannKind Corp (MNKD)
-30.93 20.59 39.62 142.64 21.70 -54.11 -27.12
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

MannKind Corp (MNKD) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of MannKind Corp (MNKD)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of MannKind Corp (MNKD)

        CEO & Director

        Dr. Michael E. Castagna Pharm.D.

        Chief Financial Officer

        Mr. Steven B. Binder

        Headquarters

        Danbury, CT

        FAQs for MannKind Corp (MNKD)

        The total asset value of MannKind Corp (MNKD) stood at $ 417 Mln as on 30-Sep-23

        The share price of MannKind Corp (MNKD) is $4.50 (NASDAQ) as of 01-Mar-2024 16:04 EST. MannKind Corp (MNKD) has given a return of -7.63% in the last 3 years.

        MannKind Corp (MNKD) has a market capitalisation of $ 1,059 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        Since, TTM earnings of MannKind Corp (MNKD) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the MannKind Corp (MNKD) and enter the required number of quantities and click on buy to purchase the shares of MannKind Corp (MNKD).

        MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. Address: 1 Casper Street, Danbury, CT, United States, 06810

        The CEO & director of Dr. Michael E. Castagna Pharm.D.. is MannKind Corp (MNKD), and CFO & Sr. VP is Mr. Steven B. Binder.

        The promoters of MannKind Corp (MNKD) have pledged 0% of the total equity as on Sep-23.

        MannKind Corp (MNKD) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        -1.01
        Dividend yield(%)
        0

        No, TTM profit after tax of MannKind Corp (MNKD) was $-33 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $1,058.53 Mln
        • Revenue (TTM)revenue-information $176.55 Mln
        • Earnings (TTM) earning-information $-33.01 Mln
        • Cash date-information $141.02 Mln
        • Total Debt info $277.53 Mln
        • Insider's Holding 2.59%
        • Liquidity liquidity High
        • 52 Week range week-range $3.17 - 5.75
        • Shares outstanding share-outstanding 269,575,008
        • 10 Years Aggregate:

          CFO: $-482.70 Mln

          EBITDA: $-679.56 Mln

          Net Profit: $-997.69 Mln

        About The Company

        • IPO Date 28-Jul-2004
        • CEO & Director Dr. Michael E. Castagna Pharm.D.
        • Chief Financial Officer Mr. Steven B. Binder
        • Listing key-listing NASDAQ: MNKD
        • Country United States
        • Headquarters headquarters Danbury, CT
        • Website website https://www.mannkindcorp.com
        • Business

          MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve...  glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. Address: 1 Casper Street, Danbury, CT, United States, 06810  Read more

        share-fund-plan-icon